Table 2.
The number of spontaneously-reported adverse events by week and treatment group *
| Adverse Event | Week 1 | Weeks 2–3 | Week 4 | |||
|---|---|---|---|---|---|---|
| Placebo | D-AMP ** | Placebo | D-AMP | Placebo | D-AMP | |
| Body Aches | 1 | --- | --- | --- | --- | --- |
| Coldness | 1 | --- | --- | --- | --- | --- |
| Constipation | --- | 1 | --- | --- | --- | --- |
| Coughing | 1 | --- | --- | --- | --- | --- |
| Decreased Appetite | 1 | --- | --- | --- | --- | --- |
| Fatigue/Low Energy | --- | 1 | 1 | --- | --- | --- |
| Flushed | --- | 1 | --- | --- | --- | --- |
| Headaches | 2 | 1 | 1 | 1 | 1 | --- |
| Heartburn | --- | 2 | --- | --- | --- | --- |
| Hot/Sweaty | --- | 1 | --- | 1 | --- | --- |
| Increased Blood Pressure | --- | 1 | --- | 1 | --- | --- |
| Increased Heart Rate | 6 | 4 | 1 | --- | 1 | --- |
| Insomnia | 1 | 2 | 1 | 1 | --- | --- |
| Itching | --- | 1 | --- | --- | --- | --- |
| Lightheaded/Dizzy | 2 | 1 | --- | 1 | --- | --- |
| Nasal Congestion | 1 | --- | --- | --- | --- | --- |
| Nausea/Vomiting | 1 | --- | --- | --- | 1 | --- |
| Paleness | 1 | --- | --- | --- | --- | --- |
| Restless Lower Extremities | 1 | --- | --- | --- | --- | --- |
| Shaking Hands | 1 | --- | --- | --- | --- | --- |
| Twitching | --- | --- | --- | 1 | --- | --- |
| Weakness | --- | 1 | --- | --- | --- | --- |
| Wheezing | 1 | --- | --- | --- | --- | --- |
| Total Number of Events | 21 | 17 | 4 | 6 | 3 | 0 |
*
Number of times adverse events were attributed as possible, probable or definite. Adverse events attributed as unrelated or unlikely were not reported. Week 1: all participants on d-amphetamine; Week2–3: participants randomized to d-amphetamine or placebo; Week 4: all participants on placebo.
**
D-AMP = D-Amphetamine.